Melanotan Dosage in the Research Literature
Phase I Dose-Escalation Data
melanotan dosage in human studies derives from a small number of Phase I trials. The 1996 Dorr pilot study — the first controlled human study of MT-II — used a 5-day dose escalation in 3 healthy males: 0.01, 0.015, 0.02, 0.025, and 0.03 mg/kg/day subcutaneous [3]. Measurable pigmentation increases were observed in 2 of 3 subjects. Nausea and somnolence were reported at higher dose levels within that escalation range.
Subsequent ED trials by Wessells et al. (1998, 2000) standardized the dose at 0.025 mg/kg subcutaneous for the controlled crossover design — a dose that produced erections in 8 of 10 (psychogenic ED) [5] and 17 of 20 (organic ED) [6] subjects. The 2000 organic ED crossover trial in 10 men replicated the 0.025 mg/kg dose and confirmed erection duration ~45 minutes vs. 1.9 minutes for placebo [7].
Those three trials constitute the entirety of controlled human dose data for Melanotan II. No Phase II or Phase III trials for MT-II in any indication have been completed.
Onset Timeline in Research Studies
In Phase I trials, objective colorimetric pigmentation increases were measurable at 2–4 weeks of daily subcutaneous dosing [3]. The onset and duration of pigmentation effect from the Dorr 1996 study is one of the few directly quantified onset datasets in the literature.
Subjective reports of tanning in self-administered, uncontrolled populations typically describe within-week changes — consistent with early eumelanin upregulation in response to MC1R activation, which can precede measurable colorimetric change. The 2021 qualitative analysis of 623 online forum entries from 205 MT-II users confirmed earlier perceived onset in unmonitored self-administration [23].
Note: self-reported onset data from uncontrolled populations reflects variable doses, inconsistent UV exposure, and unverified compound identity. Only the Phase I Dorr data provides controlled onset measurement.
How Long Does the Pigmentation Effect Persist?
In the Dorr 1996 Phase I trial, pigmentation increases were still measurable 4–6 weeks after the last dose; the duration was variable and correlated with baseline Fitzpatrick skin type [3].
The mechanism: plasma clearance of both MT-I and MT-II is rapid (beta half-life < 2 hours for MT-I in humans subcutaneous [17]; biphasic rapid clearance for MT-II in rats IV [18]), but melanin synthesis continues after peptide clearance. The cAMP/PKA/CREB/MITF cascade drives sustained tyrosinase expression, and melanin production continues until that expression normalizes. This dissociation between rapid peptide clearance and sustained pigmentation is a documented feature of the melanotan family [17].
Research does not support permanent pigmentation. Melanin production returns toward baseline after cessation; continued UV exposure or re-dosing appears necessary to maintain elevated pigment levels.
Is Melanotan Pigmentation Permanent?
No. The Phase I data documents 4–6 weeks of elevated pigmentation post-cessation [3], not permanence. The 2012 Sivyer case report of a 16-year-old with FAMMM syndrome who self-injected MT-II noted that moles lightened and skin color paled three months after cessation [14]. The 2026 Bonchev case report (400 µg every other day, 64 days cumulative) documented partial reversal of oral mucosal pigmentation by 28 days post-cessation, with gingival pigmentation persisting with reduced intensity at 3 months [24].
Pigmentation reversal timelines vary by tissue type, baseline melanin density, UV habits post-cessation, and dose duration. Human controlled data on reversal rates is limited to small series and case reports.
Duration of Effect After Dosing Cessation
Phase I data suggests pigmentation persists 4–6 weeks post-cessation [3]. The compound's plasma half-life in rats after IV administration is biphasic and rapid [18]; melanin synthesis continues after peptide clearance, producing the observed duration.
For the ED applications studied in Phase I, no long-term dosing duration data exists — those trials were acute crossover designs (single injection per period). Duration of erectogenic effect in active subjects: approximately 38 minutes at >80% rigidity (Wessells 1998) [5], approximately 45 minutes (Wessells 2000, organic ED) [7].
Pharmacokinetics and Half-Life
Melanotan I (afamelanotide) in humans (Ugwu et al. 1997). Absorption phase half-life 0.07–0.79 hours; beta-phase half-life 0.8–1.7 hours subcutaneous; systemic clearance 0.12–0.19 L/kg/h; oral bioavailability: undetectable [17]. Pigmentation effects persisted 3 weeks after final dose despite rapid peptide clearance, confirming that melanin synthesis continues substantially after the peptide has cleared plasma [17].
Melanotan II in rats (Ugwu et al. 1994). IV administration (0.3 mg/kg): biphasic plasma disposition confirmed by both HPLC and bioassay methods; rapid multi-compartment clearance [18]. Both compounds show rapid plasma clearance that contrasts sharply with sustained downstream melanin synthesis.
Oral route: 4.6% oral bioavailability for MT-II in rats [1]; undetectable for MT-I in humans [17]. The oral route is not viable for research use.
Melanotan Administration Routes: Injection vs. Nasal Spray
Routes studied in the published literature:
- Subcutaneous injection. Primary research and self-use route. Used in all Phase I human trials [3][5][6][7]. The cyclic structure of MT-II provides enzymatic resistance that improves bioavailability vs. linear alpha-MSH at subcutaneous sites.
- Intravenous. Used in pharmacokinetic studies (rats) [18] and female rat sexual behavior research [20]. Not a human research route.
- Intracerebroventricular. Used in rodent appetite and energy-balance research to isolate central MC4R effects [8][9]. Not applicable to human research protocols.
- Intranasal spray. Documented in self-administration case reports — not in any controlled trial. A 2025 case report documented a 22-year-old female who developed mucosal malignant melanoma of the anterior maxilla following use of unlicensed MT-II nasal spray for cosmetic tanning [25]. No safety data from controlled trials exists for this route. The HPRA (Ireland) and MHRA (UK) have issued specific warnings regarding unlicensed MT-II nasal spray products.
- Subcutaneous biodegradable implant. The approved route for afamelanotide (Scenesse) in EPP. A 16 mg implant releases MT-I slowly over 60–120 days, producing sustained plasma levels without the peak-and-trough kinetics of injection [15].
Reconstitution in Research Protocols
Laboratory protocols for lyophilized MT-II powder typically use bacteriostatic water for reconstitution at 1–2 mg/mL concentrations. Reconstituted solutions are stored at 4°C per standard peptide laboratory protocols and used within the timeframes specified in published study protocols.
The cyclic structure of MT-II confers greater enzymatic resistance than linear alpha-MSH, but lyophilized storage at controlled temperature is standard practice for all peptide research compounds. Freeze-thaw cycling degrades peptide integrity; standard protocols minimize this.